ASTH (Astrana Health Inc. Common Stock) Stock Analysis - News

Astrana Health Inc. Common Stock (ASTH) is a publicly traded Healthcare sector company. As of May 21, 2026, ASTH trades at $38.63 with a market cap of $1.93B and a P/E ratio of 82.85. ASTH moved -1.22% today. Year to date, ASTH is +41.46%; over the trailing twelve months it is +43.13%. Its 52-week range spans $18.08 to $63.20. Analyst consensus is strong buy with an average price target of $41.57. Rallies surfaces ASTH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What changed in ASTH news today?

Astrana Health Appoints George Christides to Lead Population Health Across 1.55M Patients: Astrana Health named George Christides as Interim National Medical Director to lead population health, care management and navigation across its national platform. The company supports over 20,000 providers and approximately 1.55 million patients in value-based care arrangements using its AI-powered, physician-centric technology to drive growth and outcomes.

ASTH Key Metrics

Key financial metrics for ASTH
MetricValue
Price$38.63
Market Cap$1.93B
P/E Ratio82.85
EPS$0.46
Dividend Yield0.00%
52-Week High$63.20
52-Week Low$18.08
Volume1
Avg Volume0
Revenue (TTM)$3.18B
Net Income$24.08M
Gross Margin0.00%

Latest ASTH News

ASTH Analyst Consensus

9 analysts cover ASTH: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $41.57.

Common questions about ASTH

What changed in ASTH news today?
Astrana Health Appoints George Christides to Lead Population Health Across 1.55M Patients: Astrana Health named George Christides as Interim National Medical Director to lead population health, care management and navigation across its national platform. The company supports over 20,000 providers and approximately 1.55 million patients in value-based care arrangements using its AI-powered, physician-centric technology to drive growth and outcomes.
Does Rallies summarize ASTH news?
Yes. Rallies summarizes ASTH news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is ASTH research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ASTH. It does not provide personalized investment advice.
ASTH

ASTH